Cargando…

Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology

BACKGROUND: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahim, Bahira, Gyberg, Viveca, De Bacquer, Dirk, Kotseva, Kornelia, De Backer, Guy, Schnell, Oliver, Tuomilehto, Jaakko, Wood, David, Rydén, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781265/
https://www.ncbi.nlm.nih.gov/pubmed/29368616
http://dx.doi.org/10.1186/s12933-018-0665-4
_version_ 1783294915531243520
author Shahim, Bahira
Gyberg, Viveca
De Bacquer, Dirk
Kotseva, Kornelia
De Backer, Guy
Schnell, Oliver
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
author_facet Shahim, Bahira
Gyberg, Viveca
De Bacquer, Dirk
Kotseva, Kornelia
De Backer, Guy
Schnell, Oliver
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
author_sort Shahim, Bahira
collection PubMed
description BACKGROUND: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dyslipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice. OBJECTIVES: To test the hypotheses (1) that dysglycaemia is common in patients with hypertension and/or dyslipidaemia and (2) that initial screening with the Finnish Diabetes Risk Score (FINDRISC) will decrease the need for laboratory based tests. METHODS: 2395 patients (age 18–80 years) without (i) a history of CVD or TDM2, (ii) prescribed blood pressure and/or lipid lowering drugs answered the FINDRISC questionnaire and had an oral glucose tolerance test (OGTT) and HbA1c measured. RESULTS: According to the OGTT 934 (39%) had previously undetected dysglycaemia (T2DM 19%, IGT 20%). Of patients, who according to FINDRISC had a low, moderate or slightly elevated risk 20, 34 and 41% and of those in the high and very high-risk category 49 and 71% had IGT or T2DM respectively. The OGTT identified 92% of patients with T2DM, FPG + HbA1c 90%, FPG 80%, 2hPG 29% and HbA1c 22%. CONCLUSIONS: (1) The prevalence of dysglycaemia was high in patients treated for hypertension and/or dyslipidaemia. (2) Due to the high proportion of dysglycaemia in patients with low to moderate FINDRISC risk scores its initial use did not decrease the need for subsequent glucose tests. (3) FPG was the best test for detecting T2DM. Its isolated use is limited by the inability to disclose IGT. A pragmatic strategy, decreasing the demand for an OGTT, would be to screen all patients with FPG followed by OGTT in patients with IFG.
format Online
Article
Text
id pubmed-5781265
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57812652018-02-06 Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology Shahim, Bahira Gyberg, Viveca De Bacquer, Dirk Kotseva, Kornelia De Backer, Guy Schnell, Oliver Tuomilehto, Jaakko Wood, David Rydén, Lars Cardiovasc Diabetol Original Investigation BACKGROUND: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dyslipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice. OBJECTIVES: To test the hypotheses (1) that dysglycaemia is common in patients with hypertension and/or dyslipidaemia and (2) that initial screening with the Finnish Diabetes Risk Score (FINDRISC) will decrease the need for laboratory based tests. METHODS: 2395 patients (age 18–80 years) without (i) a history of CVD or TDM2, (ii) prescribed blood pressure and/or lipid lowering drugs answered the FINDRISC questionnaire and had an oral glucose tolerance test (OGTT) and HbA1c measured. RESULTS: According to the OGTT 934 (39%) had previously undetected dysglycaemia (T2DM 19%, IGT 20%). Of patients, who according to FINDRISC had a low, moderate or slightly elevated risk 20, 34 and 41% and of those in the high and very high-risk category 49 and 71% had IGT or T2DM respectively. The OGTT identified 92% of patients with T2DM, FPG + HbA1c 90%, FPG 80%, 2hPG 29% and HbA1c 22%. CONCLUSIONS: (1) The prevalence of dysglycaemia was high in patients treated for hypertension and/or dyslipidaemia. (2) Due to the high proportion of dysglycaemia in patients with low to moderate FINDRISC risk scores its initial use did not decrease the need for subsequent glucose tests. (3) FPG was the best test for detecting T2DM. Its isolated use is limited by the inability to disclose IGT. A pragmatic strategy, decreasing the demand for an OGTT, would be to screen all patients with FPG followed by OGTT in patients with IFG. BioMed Central 2018-01-24 /pmc/articles/PMC5781265/ /pubmed/29368616 http://dx.doi.org/10.1186/s12933-018-0665-4 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Shahim, Bahira
Gyberg, Viveca
De Bacquer, Dirk
Kotseva, Kornelia
De Backer, Guy
Schnell, Oliver
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title_full Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title_fullStr Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title_full_unstemmed Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title_short Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
title_sort undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. a report from euroaspire iv a registry from the euroobservational research programme of the european society of cardiology
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781265/
https://www.ncbi.nlm.nih.gov/pubmed/29368616
http://dx.doi.org/10.1186/s12933-018-0665-4
work_keys_str_mv AT shahimbahira undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT gybergviveca undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT debacquerdirk undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT kotsevakornelia undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT debackerguy undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT schnelloliver undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT tuomilehtojaakko undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT wooddavid undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology
AT rydenlars undetecteddysglycaemiacommoninprimarycarepatientstreatedforhypertensionandordyslipidaemiaontheneedforascreeningstrategyinclinicalpracticeareportfromeuroaspireivaregistryfromtheeuroobservationalresearchprogrammeoftheeuropeansocietyofcardiology